 |
 |

Upcoming Events
- Comprehensive Training on European Regulatory Affairs including Different Registration Procedures and Variations: Expert Overview - (Jan 24, 2010) - Dubai
- Clinical Project Management - (Jan 25, 2010) - Horsham
- Excellence in Pharmacovigilance: Clinical Trials and Post Marketing - (Feb 08, 2010) - Paris
- Regulatory Affairs Part I: The IND Phase - (Feb 08, 2010) - Horsham
- Regulatory Affairs for Biologics - (Feb 11, 2010) - Horsham
- European Regulatory Affairs - (Feb 15, 2010) - Lisbon
- Introduction to Pre-marketing Clinical Safety & Pharmacovigilance - (Feb 16, 2010) - Horsham
- Introduction to Post-marketing Drug Safety & Pharmacovigilance - (Feb 18, 2010) - Horsham
- European Regulatory Affairs - (Feb 22, 2010) - San Francisco
- Overview of Drug Development - (Feb 26, 2010) - Horsham
Click here for more information
|
|  |
 |
 |
 |
|

Asia Pacific Pharma Sector Analysis November 2009
Table of Contents 1. Analyst View
2. Global Pharmaceutical Market Overview 2.1 Market Size and Growth 2.2 Leading Drugs
3. Asia-Pacific Pharmaceutical Market Overview
4. Pharmaceutical Market By Country 4.1 China 4.1.1 Market Overview 4.1.2 Future Outlook 4.1.3 Regulatory Environment 4.2 India 4.2.1 Market Overview 4.2.2 Future Outlook 4.2.3 Regulatory Environment 4.3 Japan 4.3.1 Market Overview 4.3.2 Future Outlook 4.3.3 Regulatory Environment 4.4 South Korea 4.4.1 Market Overview 4.4.2 Future Outlook 4.4.3 Regulatory Environment 4.5 Indonesia 4.5.1 Market Overview 4.5.2 Future Outlook 4.5.3 Regulatory Environment 4.6 Vietnam 4.6.1 Market Overview 4.6.2 Future Outlook 4.6.3 Regulatory Environment 4.7 Thailand 4.7.1 Market Overview 4.7.2 Future Outlook 4.7.3 Regulatory Environment 4.8 Philippines 4.8.1 Market Overview 4.8.2 Future Outlook 4.8.3 Regulatory Environment 4.9 Malaysia 4.9.1 Market Overview 4.9.2 Future Outlook 4.9.3 Regulatory Environment 4.10 Australia 4.10.1 Market Overview 4.10.2 Future Outlook 4.10.3 Regulatory Environment 4.11 New Zealand 4.11.1 Market Overview 4.11.2 Future Outlook 4.11.3 Regulatory Environment
5. Emerging Market Trends 5.1 Contract Manufacturing 5.2 Vaccine Market 5.3 Generics 5.4 Medical Tourism Market
6. Industry Restraints and Recommendation 6.1 IPR Protection 6.2 Regulatory Issues 6.3 Reimbursement Issues 6.4 Low Investments in R&D
7. Competitive Landscape 7.1 GlaxoSmithKline plc 7.2 Pfizer Inc 7.3 Sanofi-Aventis 7.4 Ranbaxy Laboratories Limited 7.5 Takeda Pharmaceutical Company Limited
Read More...
|
|  |
 |
|
 |
 |
65 NEW US VENTURE CAPITAL FIRMS ADDED TO OUR GLOBAL BIOPHARMACEUTICAL ONLINE VENTURE CAPITAL DIRECTORY; CURRENTLY INVESTING IN THE LIFE SCIENCES

Click Image to View Sample Online Pages and Profiles Access profiles under our simple search as part of a trial for FREE http://www.canbiotech.com/VCDBSearch.asp directory@canbiotech.com
SUBSCRIBE
Featuring Venture Capitalists in: Canada The US The UK Germany
Investing in: Biotechnology Pharmaceuticals Medical Devices/Diagnostics Genomics Bioinformatics/Bio-IT Healthcare Services
Online Database of Profiles Featuring: Contact Information including multiple names, titles and emails Description Preferred Stage of Investment Total Capital Under Management Level of Investment Geographic Preference Investments: Previous and/or Current Investments
SUBSCRIBE
|
|  |
 |
|
|